Use of Half-Generation PAMAM Dendrimers (G0.5–G3.5) with Carboxylate End-Groups to Improve the DACHPtCl<sub>2</sub> and 5-FU Efficacy as Anticancer Drugs

The DACHPtCl<sub>2</sub> compound (<i>trans</i>-(R,R)-1,2-diaminocyclohexanedichloroplatinum(II)) is a potent anticancer drug with a broad spectrum of activity and is less toxic than oxaliplatin (<i>trans</i>-l-diaminocyclohexane oxalate platinum II), with which i...

Full description

Bibliographic Details
Main Authors: Cláudia Camacho, Helena Tomás, João Rodrigues
Format: Article
Language:English
Published: MDPI AG 2021-05-01
Series:Molecules
Subjects:
Online Access:https://www.mdpi.com/1420-3049/26/10/2924
id doaj-8cbc70d15db14643a332a33e6ea6ffd7
record_format Article
spelling doaj-8cbc70d15db14643a332a33e6ea6ffd72021-06-01T00:02:54ZengMDPI AGMolecules1420-30492021-05-01262924292410.3390/molecules26102924Use of Half-Generation PAMAM Dendrimers (G0.5–G3.5) with Carboxylate End-Groups to Improve the DACHPtCl<sub>2</sub> and 5-FU Efficacy as Anticancer DrugsCláudia Camacho0Helena Tomás1João Rodrigues2CQM-Centro de Química da Madeira, MMRG, Universidade da Madeira, Campus da Penteada, 9000-390 Funchal, PortugalCQM-Centro de Química da Madeira, MMRG, Universidade da Madeira, Campus da Penteada, 9000-390 Funchal, PortugalCQM-Centro de Química da Madeira, MMRG, Universidade da Madeira, Campus da Penteada, 9000-390 Funchal, PortugalThe DACHPtCl<sub>2</sub> compound (<i>trans</i>-(R,R)-1,2-diaminocyclohexanedichloroplatinum(II)) is a potent anticancer drug with a broad spectrum of activity and is less toxic than oxaliplatin (<i>trans</i>-l-diaminocyclohexane oxalate platinum II), with which it shares the active metal fragment DACHPt. Nevertheless, due to poor water solubility, its use as a chemotherapeutic drug is limited. Here, DACHPtCl<sub>2</sub> was conjugated, in a bidentate form, with half-generation PAMAM dendrimers (G0.5–G3.5) with carboxylate end-groups, and the resulting conjugates were evaluated against various types of cancer cell lines. In this way, we aimed at increasing the solubility and availability at the target site of DACHPt while potentially reducing the adverse side effects. DNA binding assays showed a hyperchromic effect compatible with DNA helix’s disruption upon the interaction of the metallodendrimers and/or the released active metallic fragments with DNA. Furthermore, the prepared DACHPt metallodendrimers presented cytotoxicity in a wide set of cancer cell lines used (the relative potency regarding oxaliplatin was in general high) and were not hemotoxic. Importantly, their selectivity for A2780 and CACO-2 cancer cells with respect to non-cancer cells was particularly high. Subsequently, the anticancer drug 5-FU was loaded in a selected metallodendrimer (the G2.5COO(DACHPt)<sub>16</sub>) to investigate a possible synergistic effect between the two drugs carried by the same dendrimer scaffold and tested for cytotoxicity in A2780cisR and CACO-2 cancer cell lines. This combination resulted in IC<sub>50</sub> values much lower than the IC<sub>50</sub> for 5-FU but higher than those found for the metallodendrimers without 5-FU. It seems, thus, that the metallic fragment-induced cytotoxicity dominates over the cytotoxicity of 5-FU in the set of considered cell lines.https://www.mdpi.com/1420-3049/26/10/2924dendrimersPAMAManticancer drugsmetallodrugsoxaliplatin5-FU
collection DOAJ
language English
format Article
sources DOAJ
author Cláudia Camacho
Helena Tomás
João Rodrigues
spellingShingle Cláudia Camacho
Helena Tomás
João Rodrigues
Use of Half-Generation PAMAM Dendrimers (G0.5–G3.5) with Carboxylate End-Groups to Improve the DACHPtCl<sub>2</sub> and 5-FU Efficacy as Anticancer Drugs
Molecules
dendrimers
PAMAM
anticancer drugs
metallodrugs
oxaliplatin
5-FU
author_facet Cláudia Camacho
Helena Tomás
João Rodrigues
author_sort Cláudia Camacho
title Use of Half-Generation PAMAM Dendrimers (G0.5–G3.5) with Carboxylate End-Groups to Improve the DACHPtCl<sub>2</sub> and 5-FU Efficacy as Anticancer Drugs
title_short Use of Half-Generation PAMAM Dendrimers (G0.5–G3.5) with Carboxylate End-Groups to Improve the DACHPtCl<sub>2</sub> and 5-FU Efficacy as Anticancer Drugs
title_full Use of Half-Generation PAMAM Dendrimers (G0.5–G3.5) with Carboxylate End-Groups to Improve the DACHPtCl<sub>2</sub> and 5-FU Efficacy as Anticancer Drugs
title_fullStr Use of Half-Generation PAMAM Dendrimers (G0.5–G3.5) with Carboxylate End-Groups to Improve the DACHPtCl<sub>2</sub> and 5-FU Efficacy as Anticancer Drugs
title_full_unstemmed Use of Half-Generation PAMAM Dendrimers (G0.5–G3.5) with Carboxylate End-Groups to Improve the DACHPtCl<sub>2</sub> and 5-FU Efficacy as Anticancer Drugs
title_sort use of half-generation pamam dendrimers (g0.5–g3.5) with carboxylate end-groups to improve the dachptcl<sub>2</sub> and 5-fu efficacy as anticancer drugs
publisher MDPI AG
series Molecules
issn 1420-3049
publishDate 2021-05-01
description The DACHPtCl<sub>2</sub> compound (<i>trans</i>-(R,R)-1,2-diaminocyclohexanedichloroplatinum(II)) is a potent anticancer drug with a broad spectrum of activity and is less toxic than oxaliplatin (<i>trans</i>-l-diaminocyclohexane oxalate platinum II), with which it shares the active metal fragment DACHPt. Nevertheless, due to poor water solubility, its use as a chemotherapeutic drug is limited. Here, DACHPtCl<sub>2</sub> was conjugated, in a bidentate form, with half-generation PAMAM dendrimers (G0.5–G3.5) with carboxylate end-groups, and the resulting conjugates were evaluated against various types of cancer cell lines. In this way, we aimed at increasing the solubility and availability at the target site of DACHPt while potentially reducing the adverse side effects. DNA binding assays showed a hyperchromic effect compatible with DNA helix’s disruption upon the interaction of the metallodendrimers and/or the released active metallic fragments with DNA. Furthermore, the prepared DACHPt metallodendrimers presented cytotoxicity in a wide set of cancer cell lines used (the relative potency regarding oxaliplatin was in general high) and were not hemotoxic. Importantly, their selectivity for A2780 and CACO-2 cancer cells with respect to non-cancer cells was particularly high. Subsequently, the anticancer drug 5-FU was loaded in a selected metallodendrimer (the G2.5COO(DACHPt)<sub>16</sub>) to investigate a possible synergistic effect between the two drugs carried by the same dendrimer scaffold and tested for cytotoxicity in A2780cisR and CACO-2 cancer cell lines. This combination resulted in IC<sub>50</sub> values much lower than the IC<sub>50</sub> for 5-FU but higher than those found for the metallodendrimers without 5-FU. It seems, thus, that the metallic fragment-induced cytotoxicity dominates over the cytotoxicity of 5-FU in the set of considered cell lines.
topic dendrimers
PAMAM
anticancer drugs
metallodrugs
oxaliplatin
5-FU
url https://www.mdpi.com/1420-3049/26/10/2924
work_keys_str_mv AT claudiacamacho useofhalfgenerationpamamdendrimersg05g35withcarboxylateendgroupstoimprovethedachptclsub2suband5fuefficacyasanticancerdrugs
AT helenatomas useofhalfgenerationpamamdendrimersg05g35withcarboxylateendgroupstoimprovethedachptclsub2suband5fuefficacyasanticancerdrugs
AT joaorodrigues useofhalfgenerationpamamdendrimersg05g35withcarboxylateendgroupstoimprovethedachptclsub2suband5fuefficacyasanticancerdrugs
_version_ 1721415904153042944